DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Raxibacumab

Raxibacumab

  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

  • Pdf

    Pdf

  • Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens

    Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens

  • The Effect of Raxibacumab on the Immunogenicity of Anthrax Vaccine Adsorbed: a Phase

    The Effect of Raxibacumab on the Immunogenicity of Anthrax Vaccine Adsorbed: a Phase

  • A Review of the Efficacy of FDA-Approved B. Anthracis Anti

    A Review of the Efficacy of FDA-Approved B. Anthracis Anti

  • RAXIBACUMAB Safely and Effectively

    RAXIBACUMAB Safely and Effectively

  • Studies on Antitoxin Use for Postexposure Prophylaxis (PEP)

    Studies on Antitoxin Use for Postexposure Prophylaxis (PEP)

  • Boosting Anti-Infective Antibody and Vaccine Development

    Boosting Anti-Infective Antibody and Vaccine Development

  • 1 Supplementary Materials 1 2 Data Sources 3 in Total, 60 Antibodies

    1 Supplementary Materials 1 2 Data Sources 3 in Total, 60 Antibodies

  • Monoclonal Antibodies for Infectious Diseases

    Monoclonal Antibodies for Infectious Diseases

  • Raxibacumab: a Panacea for Anthrax Disease?

    Raxibacumab: a Panacea for Anthrax Disease?

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

  • Pharmacology and Anti-Infective Role of Raxibacumab: a Novel Monoclonal Antibody for the Treatment of Anthrax H Singh1, S Ratol2, P Thangaraju3, S Kumar1, a Goel4

    Pharmacology and Anti-Infective Role of Raxibacumab: a Novel Monoclonal Antibody for the Treatment of Anthrax H Singh1, S Ratol2, P Thangaraju3, S Kumar1, a Goel4

  • (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

    (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

  • HHS Public Access Author Manuscript

    HHS Public Access Author Manuscript

  • VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1- Exposed Infants

    VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1- Exposed Infants

  • Development and Challenges to Monoclonal Antibodies for Passive Immunization

    Development and Challenges to Monoclonal Antibodies for Passive Immunization

  • International Nonproprietary Names (INN) for Biological and Biotechnological Substances

    International Nonproprietary Names (INN) for Biological and Biotechnological Substances

Top View
  • © Copyright 2018 Dennis Ryan Goulet
  • History and Practice: Antibodies in Infectious Diseases ADAM HEY1 1Preclinical Safety, Biologics, Novartis AG, Basel, Switzerland
  • Development of Therapeutic Antibodies for the Treatment Of
  • Wo 2010/095940 A2
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2018
  • Assessment Report
  • ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
  • Anthrax Immune Globulin Improves Hemodynamics and Survival During B
  • Cross Discipline Team Leader Review
  • Monoclonal Antibody Consumption Pattern in a Sponsored Tertiary-Care Healthcare System in a Developing Country: a Five-Year Study from 2013 - 2017
  • Evaluating the Need for an Orphan Drug Act in India by Comparing It with the US Orphan
  • Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019
  • Raxibacumab: Potential Role in the Treatment of Inhalational Anthrax
  • AHFS Pharmacologic-Therapeutic Classification System
  • Biological Product Deviation Reporting and HCT/P Deviation Reporting – Non-Blood Product Codes
  • (INN) for Biological and Biotechnological Substances
  • [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
  • Anticorps Monoclonaux En Infectiologie Des Nouveaux Partenaires Dans L'arsenal Thérapeutique


© 2024 Docslib.org    Feedback